Related Experiment Video
Updated: May 12, 2026

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits (Oryctolagus cuniculus)
Published on: July 31, 2021
Extemporaneous compounding in veterinary practice: a New Zealand perspective.
D A Gargiulo1, C Chemal, L Joda
1a School of Pharmacy, Faculty of Medical and Health Sciences , University of Auckland , Private Bag 92019 , Auckland , New Zealand.
Extemporaneous compounding is common in New Zealand veterinary practices, often due to unavailable commercial products. Collaboration between veterinarians and pharmacists could enhance this service for animal patients.
Area of Science:
- Veterinary Pharmacy
- Pharmaceutical Compounding
Background:
- Extemporaneous compounding is the preparation of medications on an as-needed basis.
- This practice is essential in veterinary medicine when commercial products are unavailable or require specific dosing.
Purpose of the Study:
- To assess the prevalence of veterinary extemporaneous compounding in New Zealand.
- To explore the potential for pharmacist-veterinarian collaboration to improve compounding services.
Main Methods:
- A questionnaire survey was distributed to 200 randomly selected New Zealand veterinarians.
- Semi-structured interviews were conducted with participants from animal facilities and compounding pharmacies.
Main Results:
- A 44.5% response rate was achieved, with 37% of respondents compounding medications.
- Commonly compounded products included cyclosporin eye drops, methimazole gels, and potassium bromide solutions for dogs, cats, and cattle.
- Challenges included ingredient and dosage form unavailability, stability issues, and time constraints.
Conclusions:
- Veterinary extemporaneous compounding is a current practice in New Zealand.
- Pharmacists' expertise in formulation can benefit veterinary patients.
- Educating both professions on collaborative opportunities is recommended to improve services.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Dosage Regimens: Designs and Approaches
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...
Clinically Relevant Drug Product Specifications: Methods of Establishment

